anti-CD20/anti-CD3 bispecific antibody CM355

A bispecific antibody and novel T-cell engager1 (nTCE) targeting both the tumor-associated antigen (TAA) CD20 and the CD3, a T-cell surface antigen, with potential immunomodulating and antineoplastic activities. Upon administration, anti-cd20/anti-cd3 bispecific antibody CM355 binds to both T cells and CD20-expressing B-lineage tumor cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against the CD20-expressing tumor B cells. CD20 is exclusively expressed on B cells during most stages of B-cell development and is often overexpressed in B-cell malignancies.